GIMDx Inc reported on Wednesday the launch of an agreement for the accelerated commercialisation of IncellDx Inc's HPV E6/E7 OncoTect mRNA in situ Hybridization Detection Kit at its Chinese subsidiary, Improve Labs.
The acceleration follows the publication of China continuation patent #201711037694.6., "Methods and Systems for Predicting Whether a Subject has a Cervical Intraepithelial Neoplasia Lesion from a Suspension Sample of Cervical Cells" and the previous IncellDx China patent #201180061996.1 of the same title.
Based in Guangzhou, China, Improve Labs is a specialty cancer diagnostics laboratory officially licensed by the Chinese government (similar to a US CLIA laboratory) and is actively working with Tier 3 hospitals in Guangdong Province and greater China.
This patent allowance is expected to decrease the time required for the test to receive regulatory approval in China, added the companies.
GIMDx specialises in commercial collaborations and R&D laboratory support for IVD companies with particular emphasis on addressing China's unique market needs and is the US subsidiary of Guangzhou Improve Medical Instruments Co Ltd.
Located at Menlo Park, California, USA, IncellDx Inc is a single cell diagnostic company committed to advancing precision medicine.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886